Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Johannes Van Den Anker

Neonatal-Perinatal Medicine Washington, DC Medical Doctor

NPI 1598842957 CMS profile 408694

111 Michigan Ave Nw, Washington, DC 20010

Open in the dashboard

General payments

$165,519

107 records reported · program years 2019–2025

Research payments

$4,750

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,400 paid to institutions, not to them · program year 2023

Through program year 2025, Johannes Van Den Anker of Washington, DC is reported in the CMS Open Payments database as having received $165,519 across 107 general payments and $4,750 in research payments paid to them. Separately, studies naming them as principal investigator received $2,400 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Neonatal-Perinatal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $23,215 10
2024 General $14,210 7
2023 General $24,538 12
2022 General $18,908 12
2021 General $29,780 15
2021 Research $3,000 1
2020 General $24,025 19
2019 General $30,843 32
2019 Research $1,750 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Johannes Van Den Anker
  • Neonatal-Perinatal Medicine median
  • Middle half of Neonatal-Perinatal Medicine
  • National median

In program year 2025, general payments to Johannes Van Den Anker were reported at $23,215. Among 879 Neonatal-Perinatal Medicine profiles paid that year, the median was $77 and the middle half received between $26 and $145.

Show as a table
Year Johannes Van Den Anker Neonatal-Perinatal Medicine median Middle half National median
2019 $30,843 $70 $22–$125 $163
2020 $24,025 $39 $18–$108 $114
2021 $29,780 $49 $18–$122 $132
2022 $18,908 $47 $21–$149 $149
2023 $24,538 $49 $23–$140 $160
2024 $14,210 $65 $24–$132 $164
2025 $23,215 $77 $26–$145 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Shionogi Inc $47,440 30 payments
  2. Eli Lilly and Company $29,525 11 payments
  3. Daiichi Sankyo Inc. $24,948 21 payments
  4. Pfizer Inc. $11,532 7 payments
  5. ViiV Healthcare Company $8,000 2 payments
  6. Janssen Research & Development, LLC $7,600 4 payments
  7. American Regent $7,495 3 payments
  8. Ucb SA $6,560 4 payments
  9. Vertex Pharmaceuticals Incorporated $4,581 14 payments
  10. Intercept Pharmaceuticals, Inc. $3,640 1 payment
  11. Other $14,198 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $148,880 81 payments
  2. Travel and Lodging $12,293 14 payments
  3. Honoraria $3,640 1 payment
  4. Food and Beverage $705 11 payments
Products named General payments · program years 2019–2025
  1. Fetroja $27,290 19 payments
  2. Savaysa Thrombosis $11,900 9 payments
  3. INJECTAFER $7,495 3 payments
  4. Briviact $6,970 5 payments
  5. OCALIVA $3,640 1 payment
  6. HEMLIBRA $3,120 2 payments
  7. OPANA Pain $1,940 2 payments
  8. SAVAYSA Thrombosis $1,225 1 payment
  9. OPANA Pain $500 1 payment
  10. ELIQUIS $332 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Amgen Inc. $3,000 1 payment
  2. Endo Pharmaceuticals Inc. $1,750 1 payment

Records

109 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record